Myovant Sciences (NYSE: MYOV) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Myovant Sciences to related companies based on the strength of its risk, institutional ownership, dividends, valuation, profitability, analyst recommendations and earnings.

Institutional & Insider Ownership

79.8% of Myovant Sciences shares are owned by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 2.8% of Myovant Sciences shares are owned by company insiders. Comparatively, 15.5% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Myovant Sciences and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Myovant Sciences N/A -49.91% -45.87%
Myovant Sciences Competitors -13,597.63% -103.31% -25.61%

Earnings & Valuation

This table compares Myovant Sciences and its competitors revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Myovant Sciences N/A -$83.44 million -9.52
Myovant Sciences Competitors $563.95 million $96.15 million 54.08

Myovant Sciences’ competitors have higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings for Myovant Sciences and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myovant Sciences 0 0 6 0 3.00
Myovant Sciences Competitors 128 794 1733 59 2.63

Myovant Sciences currently has a consensus target price of $20.00, indicating a potential upside of 48.92%. As a group, “Biopharmaceuticals” companies have a potential upside of 15.14%. Given Myovant Sciences’ stronger consensus rating and higher probable upside, equities analysts plainly believe Myovant Sciences is more favorable than its competitors.

Summary

Myovant Sciences beats its competitors on 6 of the 11 factors compared.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.

Receive News & Ratings for Myovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.